NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
Commencement of Trading on Split-Adjusted Basis on December 21, 2023
BOSTON, Dec. 19, 2023 /PRNewswire/ — NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced a 1-for-8 reverse stock split of the Company’s Common Stock, par value $0.001. Beginning on December 21, 2023, the Company’s Common Stock will trade on The Nasdaq Capital Market on a split adjusted basis.
Related news for (NRBO)
- NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia – Reflecting the Company’s Focus on Cardiometabolic Diseases
- neurobo pharmaceuticals announces positive top-line data from the sad part 1 of its phase 1 clinical trial evaluating da-1726 for the treatment of obesity
- NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
- NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
- NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement